Market Data 
Markets
Replies to post #220933 on Biotech Values
10/18/19 10:57 AM
Bavarian Nordic A/S announced today that the stage 1 of the Phase 2 study evaluating the combination therapy of its cancer immunotherapy, CV301, and Roches’s checkpoint inhibitor, atezolizumab (TECENTRIQ), for the treatment of patients with locally advanced or metastatic urothelial bladder cancer did not meet the efficacy threshold to progress into stage 2 with expanded enrollment.
AI
